Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ16269110 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | JNJ16269110 5 mg twice daily for 12 weeks |
| 002 | EXPERIMENTAL | JNJ16269110 10 mg twice daily for 12 weeks |
| 003 | EXPERIMENTAL | JNJ16269110 15 mg twice daily for 12 weeks |
| 004 | PLACEBO_COMPARATOR | Placebo twice daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| JNJ16269110 | DRUG | 5 mg twice daily for 12 weeks |
| Placebo | DRUG | twice daily for 12 weeks |
| Metformin | DRUG | Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study. |
| Dietary Counseling | OTHER | Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study. |
Inclusion Criteria: * History of Type 2 Diabetes Mellitus and treated with a stable dose of metformin for at least 2 months * Women must be postmenopausal or surgically incapable of childbearing or if sexually active, be practicing an effective method of birth control * BMI between 25 and 45 kg/m2 ...
JNJ16269110 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its safety and effectiveness in patients with this condition.
JNJ16269110 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical trials to evaluate the drug's potential in treating Type 2 Diabetes Mellitus.
JNJ16269110 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received approval from regulatory agencies. The drug is being studied for its safety and effectiveness in patients with Type 2 Diabetes Mellitus.
JNJ16269110 has been studied in one completed Phase 2 clinical trial registered as NCT00672386. This randomized, double-blind, placebo-controlled study enrolled 352 participants with Type 2 Diabetes Mellitus across multiple countries including Belgium, Denmark, Finland, Germany, India, Netherlands, Norway, Poland, Russia, Sweden, and the United Kingdom.
JNJ16269110 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Type 2 Diabetes Mellitus. The drug has completed one clinical trial, but it has not yet received regulatory approval and remains under investigation for its safety and effectiveness.